| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $4,999,999 | 1 | 13 |
Sells | $42,588 | 7 | 87 |
| GOODMAN COREY S | 1 | $5M | 0 | $0 | $5M | |
| Wong Shelly | SVP, FINANCE AND CAO | 0 | $0 | 2 | $3,970 | $-3,970 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 0 | $0 | 2 | $31,019 | $-31,019 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of …
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $5M and sold $42,588 worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $1.79M and sold $4.5M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GOODMAN COREY S () — $5M.
The last purchase of 3,184,713 shares for transaction amount of $5M was made by GOODMAN COREY S () on 2026‑02‑02.
| 2026-08-17 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,230 0.0016% | $1.93 | $4,304 | -29.44% | |
| 2026-08-17 | Sale | Wong Shelly | SVP, FINANCE AND CAO | 573 0.0004% | $1.93 | $1,106 | -29.44% | |
| 2026-07-01 | Sale | Wong Shelly | SVP, FINANCE AND CAO | 1,404 0.001% | $2.04 | $2,864 | -6.31% | |
| 2026-03-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 12,311 0.0225% | $2.17 | $26,715 | -13.01% | |
| 2026-03-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 903 0.0017% | $2.17 | $1,960 | -13.01% | |
| 2026-02-18 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 565 0.001% | $2.27 | $1,283 | -16.38% | |
| 2026-02-02 | GOODMAN COREY S | 3.18M 5.4893% | $1.57 | $5M | +16.67% | |||
| 2026-01-06 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 3,925 0.0072% | $1.11 | $4,357 | +78.70% | |
| 2025-09-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 71,163 0.1367% | $1.08 | $76,892 | +75.24% | ||
| 2025-09-16 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 21,070 0.0388% | $1.07 | $22,461 | +70.37% | ||
| 2025-08-18 | Shantharam Harish | Chief Financial Officer | 75,000 0.1123% | $0.78 | $58,403 | +75.10% | ||
| 2025-08-15 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,382 0.0044% | $0.64 | $1,525 | +163.85% | |
| 2025-08-15 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 611 0.0011% | $0.64 | $391 | +163.85% | |
| 2025-07-07 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 2,011 0.0038% | $0.45 | $905 | +253.60% | |
| 2025-06-30 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,532 0.003% | $0.43 | $659 | +273.40% | |
| 2025-02-19 | Sale | Pons Jaume | PRESIDENT & CSO | 1,326 0.0025% | $1.15 | $1,525 | -10.92% | |
| 2025-02-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,159 0.004% | $1.15 | $2,483 | -10.92% | |
| 2025-02-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 550 0.001% | $1.15 | $633 | -10.92% | |
| 2025-01-06 | Sale | Pinto Shelly | Interim CFO | 2,221 0.0043% | $1.80 | $3,998 | -41.06% | |
| 2024-12-30 | Sale | Pons Jaume | PRESIDENT & CSO | 10,796 0.02% | $1.58 | $17,060 | -36.45% |
| GOODMAN COREY S | 8453038 6.1131% | $10.9M | 2 | 0 | +90.48% | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 294379 0.2129% | $379,748.91 | 4 | 8 | +38.82% |
| Adelman Robert J | 5268325 3.81% | $6.8M | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 0.7196% | $1.28M | 2 | 0 | +34.88% |
| Vivo Capital IX, LLC | 10 percent owner | 789474 0.5709% | $1.02M | 1 | 0 | +90.48% |
| LSV Associates, LLC | 10 percent owner | 285956 0.2068% | $368,883.24 | 1 | 4 | +90.48% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.0885% | $157,828.92 | 2 | 8 | +4.18% |
| Shantharam Harish | Chief Financial Officer | 75000 0.0542% | $96,750.00 | 1 | 0 | +75.1% |
| Hemrajani Rekha | director | 33000 0.0239% | $42,570.00 | 2 | 0 | +27.02% |
| Pietzke Steffen | VP Fin & Chief Acct Officer | 3000 0.0022% | $3,870.00 | 1 | 0 | +90.48% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$41,526,694 | 30 | 23.89% | $135.61M |
| Increased Positions | 27 | +39.71% | 3M | +10.28% |
| Decreased Positions | 26 | -38.24% | 1M | -5.11% |
| New Positions | 9 | New | 237,671 | New |
| Sold Out Positions | 10 | Sold Out | 1M | Sold Out |
| Total Postitions | 69 | +1.47% | 29M | +5.17% |
| Venbio Partners Llc | $11,155.00 | 17.96% | 9.7M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $3,833.00 | 6.17% | 3.33M | -58,472 | -1.72% | 2025-09-30 |
| Millennium Management Llc | $3,016.00 | 4.86% | 2.62M | +2M | +432.44% | 2025-09-30 |
| Almitas Capital Llc | $2,917.00 | 4.7% | 2.54M | -1,464 | -0.06% | 2025-09-30 |
| Vanguard Group Inc | $1,758.00 | 2.83% | 1.53M | -72,189 | -4.51% | 2025-09-30 |
| Acadian Asset Management Llc | $1,404.00 | 2.26% | 1.22M | -47,174 | -3.72% | 2025-09-30 |
| Driehaus Capital Management Llc | $915.00 | 1.47% | 795,777 | +795,777 | New | 2025-09-30 |
| Two Sigma Advisers, Lp | $828.00 | 1.33% | 719,800 | +16,500 | +2.35% | 2025-09-30 |
| Ameriprise Financial Inc | $751.00 | 1.21% | 652,897 | +652,897 | New | 2025-09-30 |
| Two Sigma Investments, Lp | $698.00 | 1.12% | 606,671 | +128,737 | +26.94% | 2025-09-30 |